AstraZeneca/Merck's Lynparza gets EMA panel nod for expanded use in breast cancer subtype
Waldemarus/iStock via Getty Images


A panel of the European Medicines Agency (EMA) recommended the expanded approval of AstraZeneca (NASDAQ:AZN) and Merck's (MRK) blockbuster cancer drug Lynparza.
The EMA's Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion on Lynparza for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer, who have been previously treated with neoadjuvant or adjuvant chemotherapy.

Merck said the CHMP decision was backed by data from a Phase 3 trial called OlympiA.
Lynparza generated $792M in revenue in Q1, according to AstraZeneca's Q1 report. The drug is also approved to treat certain patients with ovarian, breast, prostate and pancreas cancers in the EU.